[This review was originally posted at the Nieman Journalism Lab Synthroid Dosage, on Oct. 21, 2011.]
Growing tension at News Corp.: We'll be hearing the news from News Corp.'s annual shareholder meeting later today, and media observers are certainly watching the meeting closely, especially after reports late last week that numerous groups representing about a quarter of the company's investors are planning on voting against many of News Corp.'s board members.
The list of problems at News Corp. has continued to lengthen over the past three months, What is Synthroid, and an analyst interviewed by NPR's David Folkenflik asserted that in an ordinary company, the board would have fired the CEO by now. But Rupert Murdoch, of course, is no ordinary CEO. But even in the close-knit top leadership of News Corp., this scandal is leading to significant tension between Murdoch and his son, James, who was until recently the company's heir apparent, Synthroid Dosage. A New York Times report this week gave details of the power struggles in the Murdoch family, and Reuters' Jack Shafer pointed out that public family squabbles aren't new for the Murdochs.
Both media analyst Alan Mutter and the Guardian's Dan Gillmor were doubtful, after Synthroid, however, that the complaints of investors would make any sort of difference in the way News Corp. is run, especially since Murdoch has a 40% share in the company. "As long as Rupert Murdoch is in control, there are only two factors that will lead to change: a genuine threat to his family's money and power, Purchase Synthroid online, " Gillmor said. Synthroid Dosage, Without those threats, he argued, shareholders aren't going to see a change in direction.
And amid all of this, News Corp.'s various scandals continue to play out publicly. On the phone-hacking front, an attorney who did work for News Corp. told Parliament that he knew the company had misled Parliament about the extent of the hacking but did nothing about it.
And on the Wall Street Journal's circulation inflation, News Corp. reportedly knew about the issue almost a year before its executive resigned over it, Synthroid coupon, and Poynter's Steve Myers found that WSJ Asia also relies heavily on deeply discounted issues. But the Journal isn't the only one that relies on those discounted circulation ploys: The Guardian's Roy Greenslade noted that three major U.K, Synthroid Dosage. papers do, and Poynter's Rick Edmonds said some U.S. papers do as well. Media analyst Frederic Filloux warned of the effects of this kind of culture of cheating: "such tricks push prices further down because media buyers increasingly distrust the system. Today, Synthroid from canada, they apply the rule 'you cheat, we cut prices'. And the downward spiral continues."
Getting identity right online Synthroid Dosage, : Google+ announced a big change in its policies this week, giving word that it will soon amend its real-names-only rule to allow pseudonyms. That policy has been the subject of much debate over the past couple of months, and the coming change prompted Electronic Freedom Foundation to declare victory. Programmer Jamie Zawinski called that statement "shamefully credulous" and wondered why it's going to take months to implement. He predicted that Google+ will still require real names, but will allow nicknames and pseudonyms in addition.
Before its change, Synthroid mg, Google+ had drawn some more criticism for its identity policy. Christopher "moot" Poole has been one of the more prominent advocates for anonymity online — it's central to 4chan, the image-based message board he founded — and he articulated his position again this week in a short tech-conference speech, Synthroid Dosage. (Good summaries by VentureBeat and ReadWriteWeb.) This time, he targeted the identity policies of Facebook and Google+, saying they try to force-fit people into a single identity, when they're really much more complex than that.
"Google and Facebook would have you believe that you’re a mirror, Get Synthroid, but we’re actually more like diamonds," Poole said. "Look from a different angle, and you see something completely different." He argued that Google+ missed a big opportunity to innovate by allowing users to manipulate who they share with, rather than who they share as. Twitter has a better handle on identity, he said, as an interest-based community, japan, craiglist, ebay, overseas, paypal, rather than an identity-based one.
Wired's Tim Carmody praised Poole's philosophy of identity Synthroid Dosage, , arguing that it's practical without surrendering to Facebook's one-identity-for-all-time mantra. And GigaOM's Mathew Ingram also praised Twitter's approach, arguing that its commitment to free speech is far more important than whether participants are using their real names.
Making nonprofit news sustainable: The Knight Foundation released a comprehensive report on what makes local nonprofit news organizations work, featuring profiles of eight orgs, including many of the big names in that corner of the news world — Bay Citizen, Generic Synthroid, MinnPost, Voice of San Diego, Texas Tribune, and so on.
The study highlighted three keys to sustainability for local nonprofit news orgs: First, a workable business development strategy, which means that even if they start with foundation support, they need to treat it as something that will diminish over time, Synthroid dangers, rather than an ongoing revenue stream. Second, they need innovative approaches to building engagement both online and offline. And third, they need the skills to go deep into data journalism and interactive features, which "require technological capacity that sits outside the experience of many journalists."
Poynter's Rick Edmonds dug deeper into the study, noting a couple of other interesting tidbits: Though the sites are working hard to diversify their funding, more than half of it is still coming from foundations, and another third from donations, Synthroid Dosage. He also said these news sites need to have deep community roots and be able to adapt to specific local information needs, rather than just having a general "replace what's gone" goal.
Apple's Newsstand starts strong: It's only been around a little more than a week, but according to a couple of app sellers, Synthroid description, the early indicators on Apple's new Newsstand have been quite positive. Exact Editions and Future, two companies that produce and sell apps for publishers, said that sales have more than doubled across the board since Newsstand's launch, according to paidContent. The Daily was the biggest winner, coming out No. 1 on Newsstand's first bestseller list, taking Synthroid. Synthroid Dosage, While noting that it's very early, Jessica Roy of 10,000 Wordscalled the news "incredibly encouraging for digital publishers."
At the Knight Digital Media Center, Amy Gahran wondered whether Newsstand's popularity and ease of use will eventually spell the end of standalone iPhone and iPad news apps. That may not be a bad thing, she said: "Standalone news apps may look cool, but cumulatively they’re also a hassle for users who mainly just want access to content, not special interactive features." Meanwhile, another news org, the Economist, Synthroid used for, has had to give in to Apple's requirements that app payments go through its App Store, rather than through the web.
Reading roundup: Here's what else went on in the world of news and tech in the past week:
— Google announced it would shut down a few services: Code Search, which lets people look up open-source code, and two social networks, Jaiku and Google Buzz. ReadWriteWeb's Marshall Kirkpatrick reflected on Buzz's privacy problems, and j-prof Josh Braun said Buzz reminds us that a social network site doesn't have to be huge to be priceless, buy Synthroid no prescription. Mathew Ingram of GigaOM wondered if Google has really learned all that much from Buzz and Jaiku.
— The New York Times' David Streitfeld wrote on Amazon's burgeoning business as a book publisher, both online and in print, Synthroid Dosage. Mathew Ingram told publishers to wake up and realize that they're a middleman that people are figuring out how to eliminate.
— The Guardian gave an update after a week its open-newslist experiment, reporting that it's drawn quite a bit of interest from readers and that it's been expanded to include longer-range plans. The Journal Register Co.'s Steve Buttry noted that some of his company's papers are doing this, too. Online buying Synthroid, — After its initial five-year run ended, the Knight Foundation announced its Knight News Challenge will continue in 2012, being run three times a year.
— The real-time web got a real breaking-news test yesterday when the news of former Libyan leader Muammer Gaddafi had died broke with numerous conflicting reports. Poynter's Julie Moos looked at how major news sites handled the uncertainty.
— It's something that's harped on for at least a decade, but Poynter's Mallary Jean Tenore showed that news orgs still have a ways to go in providing accessible contact information for their journalists.
Similar posts: Flagyl Over The Counter. Bactrim Dosage. Zoloft Cost. Cipro no prescription. Taking Retin A. Order Flagyl from mexican pharmacy.
Trackbacks from: Synthroid Dosage. Synthroid Dosage. Synthroid Dosage. Synthroid dosage. Buy generic Synthroid. Generic Synthroid.
[This review was originally posted at the Nieman Journalism Lab Purchase Cipro, on Sept. 2, 2011.]
Hurricane news' innovation and hype: The big U.S. news story this week was Hurricane Irene, which hit the East Coast and New England last weekend. It was a story that hit particularly close to home for many of the U.S.' leading news organizations, which led to some innovative journalism, but also some questionable coverage, Cipro treatment, too.
Several news organizations temporarily took down their online paywalls during the storm, led by the New York Times and the Long Island newspaper Newsday. The Times also used the storm as an opportunity to introduce a new Twitter account devoted to curation of information on Twitter by the paper's editors, Purchase Cipro. The Lab's Megan Garber noted that the account is incorporating much more conversation than the Times' other official Twitter accounts, and Jeff Sonderman of Poynter talked to the Times about its goal with the account — to provide a space for faster, more unrestrained information from the Times on Twitter. Cipro street price, Another good example of storm-related news innovation: The Journal Register Co.'s Ben Franklin Project.
Irene was also a big occasion for TV news, which trotted out the usual round-the-clock coverage and on-location weather-defying reports. After the storm passed through, many questioned whether news organizations had gone over the top in their breathless coverage of Irene. The Daily Beast's Howard Kurtz accused cable news Purchase Cipro, of being "utterly swept away by the notion that Irene would turn out to be Armageddon," and at the Boston Herald, Michael Graham called the Irene coverage "a manufactured media product with a tenuous connection to the actual news."
Others (many outside the TV news industry) pushed back against those charges: Northeastern j-prof Dan Kennedy said that the storm's damage actually largely matched the coverage; it just seemed like it fizzled out because that damage wasn't near New York or Washington. The New York Times' Nate Silver took a more scientific approach and made a similar conclusion, showing that the amount of Irene coverage was generally in line with that of previous storms, when the level of damage was factored in, Cipro dose.
Poynter's Julie Moos, who put together a great summary of the hurricane hype debate, also argued that Irene's severity matched the level of coverage, providing along the way a useful six-part measuring stick for journalistic hype. "The perception of hype is fed by the gap between supply and demand," she said. "Journalists must make more closely calibrated decisions than ever about what information to provide."
Social network as identity service: Google CEO Eric Schmidt threw some more fuel onto the slow-burning argument over Google+ and real names when he said at a conference last weekend that the new social network is essentially an "identity service with a link structure around your friends" — a way for others on the Internet to verify your identity and communicate with you under that identity. Where can i cheapest Cipro online, Asked about the risks to some people of such a hard-and-fast online identity, Schmidt replied that, well, they don't have to use Google+ then.
It was quite a telling quote regarding Google+'s true purpose — one that several commentators seized on, Purchase Cipro. Mashable's Pete Cashmore described the battle between Google and Facebook over web identity and reasoned that the reason Google is taking a hard line on real names is that it needs its identity system to be more reliable than Facebook's. Venture capitalist Fred Wilson said now we officially know who the real-names policy is really for: Google, not us. "The answer to why you need to use your real name in the service is because they need you to," he said, where to buy Cipro.
GigaOM's Mathew Ingram used the statement to tie together his description of what's at stake in the identity competition — the more accurate and detailed identities are, the more advertisers will pay for them. Tech blogger Dave Winer was more blunt: Google+ is a bank, he said. Purchase Cipro, They need people's real names because they want to move money around, like any other business. At the Guardian, tech writer Cory Doctorow argued that we need to open up this discussion about online identity, Cipro class, and that the single-identity philosophy Google's espousing isn't in our best interests.
Meanwhile, this month's Carnival of Journalism blog ring wrote about Google+, with several writers urging journalists and academics to "just use it," as the University of Colorado's Steve Outing put it. Spot.Us' David Cohn put the rationale well: "The reason to be on Google+ isn’t because it’s the newest, hottest, sexiest thing, Cipro from canadian pharmacy. ... You should be on these sites to understand how people are communicating and the vocabulary of this communication."
CNN grabs Zite: Major news organizations have been itching to jump into the increasingly crowded market for tablet-based news readers, and this week CNN made its own play, snatching up Zite, the personalized, magazine-like iPad news app launched in March. All Things Digital's Kara Swisher put the purchase price between $20 million and $25 million and explained the simple reason for CNN's interest: They're trying to acquire the technology to keep up with audiences that are quickly moving onto mobile platforms for their news, Purchase Cipro.
Zite will continue to operate as a separate unit, Cipro long term, across the country from CNN's headquarters. According to mocoNews' Tom Krazit, CNN will help Zite scale up to a bigger audience, while Zite will work to improve CNN's mobile offerings. And when asked by Mashable's Lauren Indvik about adding ads, CNN execs said they're going to build up the product first and worry about the business model later. Mathew Ingram of GigaOM said Zite can help CNN learn what people are sharing, why, Cipro use, and how they want news presented in a mobile format.
WikiLeaks' inadvertent cable release Purchase Cipro, : This week marked what looks like the beginning of a new, bizarre confusing chapter in the WikiLeaks saga. The story's been a bit of a confusing story, but I'll try to break it down for you: Ever since last November, WikiLeaks has been gradually releasing documents from its collection of diplomatic cables. But over the past couple of weeks, the full archive of 251, Cheap Cipro no rx, 000 cables was inadvertently released online, without sensitive information redacted, as WikiLeaks had been doing.
WikiLeaks blamed the Guardian, the British newspaper with which it had been working, for publishing the password to the hidden document files in a book about WikiLeaks earlier this year. The Guardian responded that it was told when it was given the password that it was temporary, to be changed within a day, purchase Cipro for sale.
In the meantime, as Der Spiegel explained well, Daniel Domscheit-Berg had defected from WikiLeaks with the server that contained the files, and other WikiLeaks supporters spread the files around to keep them from being taken off the web, Purchase Cipro. Once the password leaked out, the contents of the files gradually started spilling online, and by Wednesday night, they were completely public, according to Der Spiegel. It's not entirely clear what WikiLeaks will do with the files now, Cipro duration, but that's where the conflict stands.
FT pulls out of the App Store: Back in June, the Financial Times became the first major news organization to develop an HTML5 app for Apple's App Store, allowing it to design a single app for multiple platforms and to handle subscriptions outside of the app itself, which gave it a way around Apple's 30% cut. FT removed the app from the App Store this week instead of complying with Apple's requirement that all subscriptions be handled within apps.
As paidContent's Robert Andrews explained Purchase Cipro, , FT can still make money off of existing iPad app users, but the paper says most of its users have switched over the web app, and its web app use is growing quickly enough that this isn't a big loss anyway. As GigaOM's Darrell Etherington pointed out, this could be an important test case in whether a news organization can replace its Apple-based app business with an HTML5-based web app, comprar en línea Cipro, comprar Cipro baratos.
A new generation of campaign reporters: We're starting to hurtle toward full-on presidential campaign season in the U.S., and according to the New York Times, many of the reporters who'll be covering it are 20-somethings, mere babes in the dark, scary woods of campaign journalism. The Times did a trend story on these young reporters, Doses Cipro work, focusing on a boot camp for them put on by CBS and National Journal. Among the advice they're getting: Be careful to slip up in public view, and don't break news on Twitter.
Mocking, of course, ensued, Purchase Cipro. Village Voice's Rosie Gray said CBS and National Journal are asking to get beat on big stories with their Twitter policy, and Alex Pareene of Salon said the moral of the story is that modern campaign journalism is so inane that it can be pushed off to barely experienced reporters without anyone being the wiser. The Columbia Journalism Review's Erika Fry had perhaps the most substantive concern: Why are these reporters being taught primarily about avoiding gaffes, rather than actually doing good journalism.
Reading roundup: Here's the rest of what happened in this crazy-busy news week:
— The New York Times' public editor, buy Cipro from canada, Arthur Brisbane, wrote a column criticizing the Times' popular DealBook site for missing large-scale economic issues in favor of small, incremental daily stories. Times business editor Larry Ingrassia fired back with a defense of DealBook, and Reuters financial blogger Felix Salmon also defended DealBook, saying Brisbane was making a false either-or distinction, among other errors. Purchase Cipro, — A few more reflections and analyses of Steve Jobs' impending departure as Apple CEO, announced last week: The New York Times' David Carr on what he changed, and Wired's John C. Abell on Jobs' legacy and Tim Carmody on Jobs and the arts.
— He's made the point before in different ways, but NYU j-prof Jay Rosen's analysis of why the system of political news coverage is broken is still worth a read. He also followed it up with a rethinking of what political journalism could be.
— Finally, NPR's Matt Thompson wrote a great piece on what journalists can learn from the scientific method, tying together some useful big ideas.
Similar posts: Order Diflucan. Bactrim No Rx. Purchase Diflucan. Low dose Diflucan. Kjøpe Flagyl på nett, köpa Flagyl online. Bactrim treatment.
Trackbacks from: Purchase Cipro. Purchase Cipro. Purchase Cipro. Online buy Cipro without a prescription. Cipro online cod. Buy Cipro online cod.
[This review was originally posted at the Nieman Journalism Lab Bactrim Dosage, on Aug. 26, 2011.]
Apple begins life after Jobs: This week in the media and tech world was defined by three men's departures, all announced on Wednesday. By far the biggest was Steve Jobs' resignation as CEO of Apple, 35 years after he founded the company. The decision was largely health-driven, as Jobs was diagnosed with pancreatic cancer in 2004, Bactrim dosage, underwent a liver transplant in 2009, and has been on medical leave since January. Jobs will continue to be Apple's chairman, and as the Wall Street Journal reported, he'll still be involved in product development.
The announcement has drawn a massive amount of commentary, and Techmeme is the best place to gorge yourself on it — or you can read Adam Penenberg's mashup, Bactrim Dosage. Here's a small selection of some of the most interesting stuff, Bactrim canada, mexico, india, starting with the reflections on Jobs' legacy: All Things Digital's Walt Mossberg put together a sharp little rundown of the ways Jobs has changed the computing, animation, music, and mobile media industries. (TV is next.) Tech blogger John Gruber marveled at the company Jobs has built, saying, "Jobs’s greatest creation isn’t any Apple product. It is Apple itself."
Om Malik of GigaOM said Jobs taught us that building the future requires taking the long view, buy Bactrim from mexico, and tech guru Robert Scoble praised Jobs as a CEO who genuinely cared about his products, not just profits. If you're looking for more on Jobs himself, Byliner highlighted seven definitive profiles of the man from the past 15 years. Bactrim Dosage, Jobs' successor is Tim Cook, an Alabaman who joined Apple in 1998 and has been the company's chief operating officer since 2007. Cook has served as interim CEO twice, and he's essentially been acting as CEO throughout Jobs' medical leave this year. My Bactrim experience, Reuters profiled Cook, and All Things Digital's John Paczkowski said that while he's not going to be the visionary leader that Jobs was, he's the steady hand that Apple needs right now. The Atlantic's Nicholas Jackson said that Cook has learned to emulate Jobs as well as anyone could and noted all of the successful launches he's presided over. Wired's Tim Carmody wrote the most thorough defense of Cook as Jobs' successor, detailing his history with the company and his logistics innovations in particular.
The consensus on the Jobs-to-Cook transition seemed to be that Apple is losing a uniquely influential, irreplaceable CEO, but that the company is strong enough to stay well ahead of its competition anyway. Business Insider's Matt Rosoff cataloged what Apple will lose with Jobs, and msnbc.com's Wilson Rothman took stock of where Apple stands as Jobs leaving, suggesting that it might need to start working harder to fight for market share, Bactrim Dosage. Slate's Farhad Manjoo argued that Jobs has set his company up perfectly to continue his success, and Reuters' Felix Salmon predicted this transition will go down as a textbook example of a well-executed succession plan, what is Bactrim. Cook, for his part, assured Apple employees that the company's not going to change.
Two media legends leave their posts: The other two men to depart were in the media world: Poynter's pioneering media blogger Jim Romenesko and Slate media critic Jack Shafer. Romenesko, who's been running the definitive blog for news on the journalism business since the late '90s, Bactrim used for, will be semi-retiring in January, occasionally contributing reported media pieces to Poynter and doing some writing on a new personal site. The Huffington Post's Michael Arrington broke the news Bactrim Dosage, , and Romenesko's editor, Julie Moos, explained it from Poynter's perspective, detailing their ongoing transition of Romenesko to a group blog.
Poynter's Bill Mitchell told the story of Romenesko's tenure at Poynter, and touched on some of the enormous influence he's had: He chronicled one of the most important eras in journalism, helped aggregation be seen as a journalistic craft, and "brought transparency to newsrooms, equipping readers and staffers alike to hold those organizations accountable in the way that they scrutinize the operations of others."
The American Journalism Review's Rem Rieder also reflected on Romenesko's impact, and others chimed in on Twitter: Rare Planet's Patrick Thornton said he "showed journalists that good curation is journalism, get Bactrim," and the New York Times' Brian Stelter (who founded TVNewser) and paidContent founder Rafat Ali said he inspired them to start their sites. And while Wired's Tim Carmody called him "Twitter before Twitter," Romenesko himself told the New York Times he found himself disoriented by the rise of social media, saying, "My role kind of vanished."
Shafer was one of four laid off from Slate, where he had written about media since 1996, Japan, craiglist, ebay, overseas, paypal, the year the site was founded. Just hours before the news came down, the American Journalism Review had posted a profile of Shafer, with several luminaries praising his fearlessness and his meticulous research and reporting.
The layoff spurred a lot of confusion and complaints on Twitter and elsewhere, led by AJR's Rem Rieder, who called the decision "befuddling and disappointing." Northeastern j-prof Dan Kennedy also questioned the move, calling Shafer a "dogged reporter in a field where too many media critics would prefer to sit back and pontificate" and praising his iconoclastic perspective in an environment dominated by lockstep liberals and conservatives, fast shipping Bactrim.
Media critic Erik Wemple of the Washington Post said the layoffs weren't so preposterous given the financial struggles of Slate's owner, the Washington Post Co., but Forbes' Jeff Bercovici wondered if Slate's general-interest approach to the web still makes sense, Bactrim Dosage. Hamilton Nolan of Gawker used the occasion to opine on the decline of the media critic. Shafer, meanwhile, talked to Adweek about how he approached his job and what's next for him.
What should online identity be?: As Google+ grows, it's also drawing its share of detractors in the tech world, Online buying Bactrim, with various gripes about the new social network. Tech guru Robert Scoble, one of Google+'s heaviest users, also said it won't be ready to go beyond the tech crowd until it finds a way to cut down on the noise. GigaOM's Mathew Ingram echoed that thought and added a complaint about the difficulty of finding new users to connect with. Others are pushing back against that: The Huffington Post's Craig Kannalley said Google+ has all the building blocks Bactrim Dosage, of a successful platform, and MySpace founder Tom Anderson said you'll eventually be using it.
One of the primary complaints about Google+ since its launch has been its real-names policy, and Mathew Ingram continued to beat that drum this week, saying that Google lacks transparency about its motives, suggesting that Google allow any pseudonym users desire but also offer verified identities for users that request it, Bactrim mg.
Web editing veteran Derek Powazek defended Google, arguing that the notion that no one on the web uses their real name is dead: "Outside of a few legitimate edge cases and the occasional sci-fi fantasy, who we are online is simply who we are." Even though there's still a need for a space for anonymous speech online, he said, it's not up to corporations like Google to provide it for us.
The discussion about real names also extended again into the area of comment sections this week, Where can i buy Bactrim online, with Time's Graeme McMillan arguing that Facebook comments make those sections more civil, and the Huffington Post's Mandy Jenkins noting that Facebook comments don't necessarily solve the anonymity problem. Echo's Chris Saad said real names aren't the real issue with comment sections for media companies, and an Ad Age survey found that most online readers don't care about comments.
Integrating new media into journalism training: A note from across the pond: In a survey released this week, members of Britain's National Council for the Training of Journalists cast an emphatic vote for traditional media skills over new media expertise when it comes to the group's prestigious National Certification Examination, Bactrim Dosage. (The exam is used as a qualification for newsroom positions, and helps determine pay in some cases.)
Those results upset a number of British journalists who saw them as evidence of a technology-averse media establishment. The Guardian's Martin Belam worried that today's young journalists are being "encouraged to pay for qualifications that will equip them to work in a 90s newsroom, because the people designing the courses and the industry input they receive are all from people who cut their teeth in a 90s newsroom." J-prof Andy Dickinson called the group's desires journalism training for the common denominator, buy no prescription Bactrim online, not the future.
Numerous other journalists — Wales Online's Alison Gow, Reed Business Information's Adam Tinworth, David Higgerson of Trinity Mirror, and American Kerry Northrup — made a similar point: It's a fallacy, they said, Rx free Bactrim, to think of social media, multimedia and web proficiency as separate skills from the classic skills of reporting and storytelling — they're just other platforms on which to apply those skills.
Reading roundup: Really, there was other stuff going on this week than important people leaving their jobs. Here's a taste:
— A site called The Daily Dot Bactrim Dosage, launched this week with the goal of being "the web's community newspaper." So what does that mean. It's trying to cover the web's social networks, like Facebook, Twitter, Reddit, cheap Bactrim, and YouTube with reporting like a small-town paper might do. Adweek, Mashable, and VentureBeat have features on it, and one of its founders, Nicholas White, gave some lessons from his experience.
— A few News Corp. notes: The (News Corp.-owned) Wall Street Journal looked at how the plans to tap the phone of a 13-year-old murder victim went awry at News of the World, the Daily Beast's Brian Cathcart focused on the investigator at the center of that scandal, and the Los Angeles Times' Joe Flint looked at News Corp.'s influence-peddling game here in the U.S.
— Two posts to leave you with: Maria Popova's fantastic post here at the Lab on the new rarity in the information abundance of the web, and some more great advice for journalism students from the Online Journalism Review's Robert Niles.
Similar posts: Lipitor Dosage. Cipro Price. Armour Dosage. Japan, craiglist, ebay, overseas, paypal. Buy Glucophage from mexico. Flagyl without prescription.
Trackbacks from: Bactrim Dosage. Bactrim Dosage. Bactrim Dosage. My Bactrim experience. Cheap Bactrim. Order Bactrim online c.o.d.
[This review was originally posted at the Nieman Journalism Lab Buy Retin A No Prescription, on Aug. 12, 2011.]
Murdoch passes Wall Street's test: The fallout from News Corp.'s phone hacking scandal continued to spread this week, with the reported arrest of another former News of the World editor and the report that the ostensibly fired News Corp. British chief, Rebekah Brooks, Retin A alternatives, is still on the company payroll.
Three weeks after testifying before Parliament, Rupert Murdoch faced Wall Street analysts this week in a conference call, telling them that he's not going anywhere and that the scandal hasn't done any material damage to the company outside of News of the World. Purchase Retin A, All Things Digital's Peter Kafka said Wall Street really doesn't care about the hacking, and Murdoch didn't say much about the few questions he did get on it.
Murdoch also had to meet with News Corp.'s board, but as the New York Times' Jeremy Peters reported, the board's officially independent members include numerous people who have deep personal ties to Murdoch, Buy Retin A No Prescription. Perhaps more troubling was a different connection among one of the board members: According to Time's Massimo Calabresi, one of them is "best friends" with the district attorney leading the U.S. investigation into the company.
The Times' David Carr uncovered more hints at News Corp.'s enormous political influence here in the States, Retin A pics, detailing cases of swift approval of a merger by a Justice Department unit led by a future News Corp. executive, as well as a suspiciously dropped federal criminal case. "The company’s size and might give it a soft, less obvious power that it has been able to project to remarkable effect, Buy Retin A without prescription, " Carr concluded. Buy Retin A No Prescription, At Adweek, Murdoch biographer Michael Wolff went further, reporting that the Justice Department is considering investigating News Corp. on racketeering charges, though Forbes' Jeff Bercovici doubted that would happen. For a bit more info on the situation, here's a good Q&A with Nick Davies, the Guardian reporter who's been all over the story, order Retin A no prescription.
AOL's slap from investors: This week hasn't been a good one for AOL: After it reported a quarterly loss on Tuesday, its stock dropped by about a quarter by the end of the day. All Things Digital's Peter Kafka gave a quick explainer of why investors are so down on AOL: What little money they're making isn't coming from the all-important display advertising business. Mathew Ingram of GigaOM added more depth to that analysis, arguing that investors are doubting AOL's assurances that its two big gambles — Patch and the acquisition of the Huffington Post — will pay off, Buy Retin A No Prescription.
According to AOL CEO Tim Armstrong (paraphrased by Business Insider), Retin A price, coupon, the reason for those problems is that AOL's advertising side hasn't scaled well enough. Peter Kafka explained that AOL's advertising (especially display) is indeed up, though much of that can be attributed to the HuffPo and TechCrunch acquisitions. Forbes' Jeff Bercovici said AOL's public image problem has even damaged the previously successful HuffPo, quoting an analyst who called AOL a "dead brand." Wired's Tim Carmody decided to unite our two big stories this week and suggested that AOL would be a perfect fit for a purchase by News Corp.
Meanwhile's AOL's local-news initiative, Retin A samples, Patch, launched a Groupon-esque daily deal service, and Iowa grad student Robert Gutsche Jr.questioned Patch's standards for separating journalism and advertising — and got the runaround from Patch when he asked them about it. AOL's new daily tablet magazine, Editions, Buying Retin A online over the counter, also drew some criticism, with Fast Company's Austin Carr perturbed that it's not AOL-y enough.
A news org gets into tablets Buy Retin A No Prescription, : We've already seen numerous challengers to the iPad's early stranglehold on the tablet marketplace, but the Tribune Co. might be the first news company to try one out. CNN's Mark Milian reported that the newspaper chain is working on an Android-based tablet, which it's planning on offering it for free or very cheap to people who sign up for extended newspaper subscriptions. It's already missed a mid-August deadline for testing the tablet out, purchase Retin A online.
Media pundits didn't think much of the Tribune's idea. Wired's Tim Carmody urged the Tribune (and media companies in general) to quit developing tablets, arguing that it's way too hard to do if you're a major development company, let alone a news organization. "If major publishers are seriously prepared to blow up their primary revenue stream — print advertising — and slap together a giveaway tablet in order to save money on ink, God help them," he wrote, Buy Retin A No Prescription.
Others echoed Carmody's arguments: PaidContent's Tom Crazit called the project "a colossal waste of money for a company trying to emerge from bankruptcy." Chris Velazco of TechCrunch said the cheap-tablet model (also being talked about by Philadelphia Newspapers) isn't viable. Gizmodo's Brent Rose was less restrained: "WHY??" Morris Communications' Steve Yelvington was a little kinder to the Tribune, saying the numbers might add up, Kjøpe Retin A på nett, köpa Retin A online, but the devil's in the details.
The Times gets experimental: The New York Times has frequently made strong pushes into news innovation over the past several years, and this week it started another one, launching a new public test kitchen for projects in development. The Lab's Megan Garber explained what the site, beta620, Retin A for sale, is all about, but GigaOM's Mathew Ingram, while applauding the effort, expressed some doubt about whether the Times is really capable of developing a startup's mindset. Buy Retin A No Prescription, Tim Carmody of Wired, on the other hand, said the startup analogy isn't the right one for the Times. Retin A online cod, With these projects, he said, "The New York Times has become an openly experimental public institution. It’s less a cathedral consecrated to its own past than a free museum where patrons are invited to touch and transform everything they see." Poynter's Jeff Sonderman had some suggestions for next steps for the Times to take with beta620: experimenting with design, getting away from the long narrative article, and rethinking comments, Retin A trusted pharmacy reviews.
The real-name debate: One long-simmering debate I want to briefly catch you up on: Google+ has decided to take the Facebook route of disallowing pseudonyms, adjusting but reaffirming its policy in the face of online criticism late last month and again on Thursday. The outcry continued, voiced most prominently late last week by social media researcher danah boyd, Order Retin A from mexican pharmacy, who asserted that "'real names' policies aren’t empowering; they’re an authoritarian assertion of power over vulnerable people."
Liz Gannes of All Things Digital said she understands Google's motivations for enforcing real names and unifying everything under its umbrella within the same identity, but the idea of doing the latter is awkward at best and frightening at worst. The Atlantic's Alexis Madrigal, meanwhile, announced he's changed his mind against real-name policies, arguing that requiring real names online is a radical departure from the relationship between speech and identity in the offline world, Buy Retin A No Prescription.
Reading roundup: A few other things to keep an eye on this week:
— Amazon released a version of its Kindle app for browsers, called the Kindle Cloud Reader. GigaOM's Mathew Ingram said the browser-based e-book app (which bypasses Apple's restrictions) could be a roadmap for the future of the web, but Wired's Tim Carmody said it still doesn't get the web, Retin A without prescription.
— Google announced it's making its hand-chosen Editors' Picks a standing feature on Google News. The Lab's Megan Garber explained what Google's doing with it. Buy Retin A No Prescription, Meanwhile, James Gleick at The New York Review of Books offered a thoughtful piece on Google's domination of our online lives.
— Adweek explained an underrated obstacle to innovation and progress in news organizations' online efforts: the intractable CMS.
— Steve Buttry, now with the Journal Register Co., gave his lessons from TBD's demise on the Washington local news site's first birthday. It's short but solid. Enjoy.
Similar posts: Purchase Retin A. Order Cephalexin. Buy Zoloft No Prescription. Armour for sale. Where can i buy Cephalexin online. Synthroid without prescription.
Trackbacks from: Buy Retin A No Prescription. Buy Retin A No Prescription. Buy Retin A No Prescription. Retin A duration. Retin A images. Retin A australia, uk, us, usa.